Skip Navigation


NDT Advance Access first published online on September 3, 2008
This version published online on January 16, 2009
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfn492
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/3/703    most recent
gfn492v2
gfn492v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vervloet, M. G.
Right arrow Articles by Twisk, J. W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vervloet, M. G.
Right arrow Articles by Twisk, J. W. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Mortality reduction by vitamin D receptor activation in end-stage renal disease: a commentary on the robustness of current data

Marc G. Vervloet1 and Jos W. R. Twisk2

1 Department of Nephrology 2 Department of Epidemiology and Biostatistics, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

Correspondence and offprint requests to: Marc G. Vervloet, Department of Nephrology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Tel: +31-20-4442673; Fax: +31-20-4442675; E-mail: m.vervloet{at}vumc.nl



  Abstract

Background. Debate exists about assumed mortality effects of the use of vitamin D receptor activators (VDRA) in haemodialysis patients.

Methods. In the absence of randomized controlled trials (RCTs), current knowledge comes from several large observational studies that examined the association between the use of VDRA and mortality. In these trials, modern but complicated statistical analysis has been performed, attempting to minimize potential bias of suboptimal study design. This complexity may lead to suspicion about study results, and for this reason these results may be discarded for everyday clinical practice.

Results. In the current commentary, several crucial aspects of applied statistics are highlighted, attempting to aid practicing clinicians to properly weigh these study results in a balanced way. The difference between historical and retrospective cohort analysis is addressed, as well as the use of sensitivity analysis and propensity scores. The impact of confounding, mediation and effect modification for these studies on VDRA use is discussed.

Conclusions. It is concluded that the results from these studies appear quite robust and consistent. Furthermore, there is an increasing amount of data from experimental data suggesting mechanisms for observed beneficial effects. However, it must be kept in mind that VDRA can have adverse effects and that observational data can never replace RCTs.

Keywords: clinical trials; methodology; mortality; vitamin D receptor activation

The original version was incorrect. A new subtitle was added.

Received for publication: 31.12.07
Accepted in revised form: 7. 8.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.